Novo Nordisk Medical
This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.
Return to overview
Related Product Information
Search for more Rybelsus® resources or ask a question.